FDA Gets Investor Advice On Transparency At White House Gathering
Executive Summary
FDA recently met with venture capitalists and drug industry leaders to discuss the agency's initiative to become more transparent. While such get-togethers are not unusual, the location of this one signaled how significant the topic is to FDA. Rather than meet at the agency's still-being-renovated headquarters in White Oak, participants gathered at the White House
You may also be interested in...
FDA Ponders Whether To Publicly Discuss Pending NDAs And INDs; Should Agency Reply To Studies Published In Journals?
FDA leadership is considering whether, and to what extent, the agency should be able to publicly discuss INDs, drug applications and complete response letters
FDA Ponders Whether To Publicly Discuss Pending NDAs And INDs; Should Agency Reply To Studies Published In Journals?
FDA leadership is considering whether, and to what extent, the agency should be able to publicly discuss INDs, drug applications and complete response letters
FDA Is Expanding Transparency Efforts To Focus On Industry Questions
Sharfstein said the agency has split up its transparency efforts into three groups, adding one dedicated to explaining its inner workings to regulated industry.